Is Hepatitis B Curable?

Hepatitis B is a serious, potentially life-threatening liver infection caused by the hepatitis B virus (HBV). While it is not considered “curable” in the strictest sense—meaning complete eradication of the virus from the body is rare—it is highly manageable with modern antiviral therapies. Most adults who acquire acute hepatitis B clear the virus spontaneously within six months without treatment. However, chronic hepatitis B—defined as persistent infection lasting longer than six months—requires long-term medical supervision and often lifelong antiviral therapy.

First-line treatments include nucleos(t)ide analogues such as entecavir, tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF). These medications potently suppress viral replication, reduce liver inflammation, and significantly lower the risk of cirrhosis, hepatocellular carcinoma, and liver-related mortality. With consistent adherence, many patients achieve sustained virologic suppression—undetectable HBV DNA in serum—and improved liver histology over time.

Functional cure—characterized by loss of hepatitis B surface antigen (HBsAg), with or without seroconversion to anti-HBs—is an emerging therapeutic goal, though currently achieved in only a small minority of treated patients. Ongoing clinical trials are evaluating novel agents—including immune modulators, capsid inhibitors, and RNA interference therapeutics—that aim to increase functional cure rates.

Early diagnosis, regular monitoring of liver enzymes, HBV DNA levels, hepatitis B e antigen (HBeAg)/anti-HBe status, and liver imaging—and timely initiation of therapy are critical to preventing disease progression. Vaccination remains the most effective preventive measure, offering >95% protection against HBV infection when administered according to recommended schedules.